Psychological well being app Lissun will get $3 million for AI integration
Indian psychological well being platform Lissun has raised $2.5 million in Pre-Collection A funding led by RPSG Capital Ventures.
The startup plans to make use of the brand new funding to combine synthetic intelligence into its suite of digital psychological well being options focused at companies, colleges and households of kids with neurodevelopmental circumstances. The brand new funding may also be used to increase companies and develop the workforce.
Proceeds from the brand new funding spherical convey complete funding to $5 million. Lissun final raised greater than $1 million in seed funding final September.
Asan Medical Middle takes the lead in prescribing domestically acknowledged DTx for imaginative and prescient loss
Asan Medical Middle (AMC), one of many largest hospitals in South Korea, has began prescribing Korean-made digital therapeutic medicine for visible impairment attributable to stroke.
Vivid Mind, a mobile-based utility, supplies coaching by way of digital actuality to boost customers’ responses to visible stimuli.
AMC formally proposed the answer in September, 5 months after the South Korean authorities permitted it – The third one is for native DTx.
AMC Professor Kang Dong-hwa co-developed Vivid Mind with Nunaps (an area firm he based) and now plans to increase their DTx to hospitals domestically and overseas.
Neurophet’s newest collaboration predicts Alzheimer’s threat
Korean medical imaging synthetic intelligence firm Neurophet has introduced a brand new partnership to develop a brand new Alzheimer’s illness diagnostic platform.
The corporate mentioned in an announcement that it’ll associate with Aribio, an area biotech firm that develops remedies for neurodegenerative illnesses.
They intend to mix Neurophet’s MRI-based picture evaluation software program with Aribio’s blood-based Alzheimer’s diagnostic take a look at to detect early-stage sufferers with Alzheimer’s-positive amyloid beta protein deposits within the mind.
In keeping with a press launch, their answer is designed to make Alzheimer’s testing extra accessible and cut back the necessity for repeat testing utilizing costly amyloid PET imaging.
The collaboration between Neurophet and Aribio builds on current work in Aribio’s Section 3 international medical trial of AR1001, an oral Alzheimer’s illness remedy.
In July, Neurophet launched Neurophet AQUA AD, its newest Alzheimer’s remedy prescribing and monitoring software program.
